08
082270.KQ GemVax&KAEL Co.Ltd
- Market cap
- KRW 391B
- P/E
- -
- P/B
- 5.29x
- ROE
- -30.7%
- Dividend yield
- -
- Fundamental score
- 1.1/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 082270.KQ undervalued?
Graham numberThe Graham number of GemVax&KAEL Co.Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
GemVax&KAEL Co.Ltd fundamental analysis
5 of 21 checks passedROE 0/2
Low return on equity (-30.7%), below 10%.
ROA 0/1
Return on assets (-13.9%) is below the industry median (4.5%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share did not grow over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 1/1
Last year's EPS growth (88.3%) is above the industry median (-15.1%).
Revenue Growth 1/2
Revenue grew 2.5% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (39.1%), 40% or less.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Cash Runway 0/2
Cash covers 0.7 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 0/1
Price to book (5.3x) is above the industry median (1.1x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
GemVax&KAEL Co.Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About GemVax&KAEL Co.Ltd
GemVax&KAEL Co.,Ltd engages in the manufacturing and commercializing of resins and filters for semi-conductor and panel display production in South Korea. The company offers impregnated active carbon and inorganic adsorbent coating resins; CA filter for removing chemical pollution substances and harmful gases in semiconductor and LCD/PDP manufacturing process; adsorbent towers for air pollution prevention; and pressure facility for preventing equipment erosion within a subst…
Full company profileGemVax&KAEL Co.Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
GemVax&KAEL Co.Ltd annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 28.4B | 47.9B | 47.2B | 42.7B | 65.7B | 60.4B | 75.8B | 72.2B | 62.7B | 81.5B | 81.9B |
| Gross Profit | 9.26B | 16.2B | 17.4B | 14.6B | 25.5B | 18.9B | 21.9B | 26.0B | 19.7B | 34.9B | 29.3B |
| Operating Income | -6.23B | -1.41B | -12.9B | -5.61B | 2.12B | -2.48B | 322M | -13.6B | -38.7B | 3.57B | 1.12B |
| EBITDA | - | - | - | - | - | - | -16.1B | -22.9B | -80.3B | -471M | -12.5B |
| Net Income | -20.9B | -12.3B | -10.7B | -92.1B | 1.64B | 12.1B | -19.6B | -27.2B | -87.2B | -11.3B | -22.7B |
| EPS | -685 | -401 | -305 | -2,401 | 41 | 304 | -499 | -689 | -2,198 | -258 | -517 |
| Balance Sheet | |||||||||||
| Total Assets | 190B | 161B | 173B | 163B | 159B | 172B | 151B | 135B | 151B | 159B | 163B |
| Total Liabilities | 136B | 93.7B | 58.8B | 68.2B | 23.6B | 18.4B | 16.8B | 27.1B | 122B | 102B | 89.2B |
| Shareholders' Equity | 53.4B | 66.9B | 114B | 95.0B | 135B | 154B | 134B | 108B | 29.0B | 57.2B | 73.9B |
| Cash & Short-term Investments | 21.2B | 11.0B | 67.7B | 69.6B | 54.5B | 31.8B | 39.1B | 17.0B | 3.57B | 17.6B | 18.6B |
| Total Debt | 24.4B | - | - | 1.36B | 4.72B | - | - | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -12.7B | -62.6M | -256M | -712M | 14.0B | -3.47B | -2.96B | 3.57B | -28.4B | 1.11B | -22.6B |
| Capital Expenditure | 22.4B | 3.89B | 760M | 905M | 10.4B | 6.87B | 9.09B | 8.46B | 3.49B | 2.11B | 2.44B |
| Free Cash Flow | - | - | - | - | 990M | -13.0B | -13.8B | -5.55B | -32.1B | -1.01B | -25.0B |
| Ratios | |||||||||||
| ROE | -39.2% | -18.3% | -9.4% | -97.0% | 1.2% | 7.8% | -14.6% | -25.2% | -300.7% | -19.8% | -30.7% |
| ROA | -11.0% | -7.6% | -6.2% | -56.4% | 1.0% | 7.0% | -13.0% | -20.1% | -57.9% | -7.1% | -13.9% |
| Net Profit Margin | -73.7% | -25.6% | -22.7% | -215.9% | 2.5% | 20.0% | -25.9% | -37.6% | -139.1% | -13.9% | -27.7% |
| Debt to Equity | 0.46x | - | - | 0.01x | 0.03x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
GemVax&KAEL Co.Ltd dividends
GemVax&KAEL Co.Ltd has not paid dividends in the last 9 fiscal years.
Who owns GemVax&KAEL Co.Ltd
- Insiders 21.02%
- Institutions 7.93%
- Public & others 71.05%
- Shares outstanding 35.7M
- Free float 31.4M
GemVax&KAEL Co.Ltd company profile
- Company name
- GemVax&KAEL Co.Ltd
- Ticker
- 082270.KQ
- ISIN
- KR7082270000
- Exchange
- KOSDAQ
- Listed since
- Jun 24, 2005
- Sector
- Technology
- Industry
- Semiconductors & Semiconductor Equipment
- Employees
- 158
- Fiscal year end
- December
- Address
- 58 Techno 11-ro, Daejeon, South Korea
- Phone
- 82 4 2931 6287
- Website
- gemvax.com
About GemVax&KAEL Co.Ltd
GemVax&KAEL Co.,Ltd engages in the manufacturing and commercializing of resins and filters for semi-conductor and panel display production in South Korea. The company offers impregnated active carbon and inorganic adsorbent coating resins; CA filter for removing chemical pollution substances and harmful gases in semiconductor and LCD/PDP manufacturing process; adsorbent towers for air pollution prevention; and pressure facility for preventing equipment erosion within a substation; and 5aver, a fire evacuation mask. It also engages in the research and development of anti-cancer immunotherapeutic and peptide drugs; and provides RIAVAX, an immunotherapeutic peptide for the treatment of locally advanced or metastatic pancreatic cancer. The company was founded in 1998 and is headquartered in Daejeon, South Korea.
GemVax&KAEL Co.Ltd management
10- Kyung-Hee KimVP and Director · born 1961
- Jang-Sub YoonExec. Officer
- Chung-Mook LeeExec. Officer
- Dong-Man MinExec. Officer
- Young-Un SeoExec. Officer
- Ki-Seok ParkExec. Officer
- Sang-Duk LeeExec. Officer
- Mr. Dana Roy LeachExec. Officer
- Mr. Sang-Jae KimCEO & Representative Director · born 1966
- Hyoung Gon SongChief Exec. Officer